Medical Writing Generics and biosimilars Layperson materials in the sphere of biosimilars and generic medicines

Volume 28, Issue 2 - Generics and biosimilars

Layperson materials in the sphere of biosimilars and generic medicines


Generics and biosimilars offer effective treatment alternatives to branded reference drugs at a lower cost. Despite their widespread use, patients have mis conceptions regarding their efficacy and safety. Layperson materials offer an important means by which patients can be educated in this regard. Here, we provide an overview of generics and biosimilars, describe how layperson materials fit into this landscape from a patientcentricity and regulatory perspective, and provide example language that can be used when developing layperson-orientated materials for generics and biosimilars.

Download the full article


  1. Goel N, O’Sullivan D, Steinkoenig I, James J, Lindsay CA, Coates LC, et al., Tackling patient centricity: A report from the GRAPPA 2016 annual meeting. J Rheumatol. 2017;44:703–705; DOI: Available from:
  2. Stegemann S, Ternik RL, Onder G, Khan MA, van Riet-Nales DA. Defining patient centric pharmaceutical drug product design. Amer Assoc Pharmac Sci J 2016;18:1047–55. Available from: 10.1208/s12248–016–9938–6.
  3. Sacristan JA, Aguarón A, Avendaño-Solá C, Garrido P, Carrión J, Gutiérrez A, et al., Patient involvement in clinical research: why, when, and how. Pat Pref Adher. 2016;10:631–640.
  4. Yeoman G, Furlong P, Seres M, Binder H, Chung H, Garzya V, et al., Defining patient centricity with patients for patients and caregivers: a collaborative endeavour. BMJ Innovations 2017;3:76–83.
  5. Schindler T. The joys of the impossible: The writing of lay summaries of clinical study results. ClinicalTrialsArena [Internet]. 2016 December 20 [cited 2019 April 24]. Available at Available from: /the-joys-of-the-impossible-the-writing-oflay- summaries-of-clinical-study-results- 5697962–2/.
  6. Gillow CL. Layperson summaries of clinical trial results: Useful resources in the vacuum of regulatory guidance. Med Writ. 2015;24:205–209.
  7. European Commission. Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use. February 2018. Available at: Available from: files/files/eudralex/vol-10/2017_01_26_ summaries_of_ct_results_for_laypersons. pdf.
  8. Isaacs J, Gonçalves J, Strohal R, Castañeda- Hernández G, Azevedo V, Dörner T, et al., The biosimilar approval process: how different is it? Consider Med. 2017;1:doi: 10.1136/conmed-2017–100003.
  9. Alrasheedy A, Hassali MA, Stewart K, Kong D, Aljadhey H, Ibrahim MIM, et al., Patient knowledge, perceptions, and acceptance of generic medicines: a comprehensive review of the current literature. Pat Intell. 2014;6:1–29.
  10. Sanchez CK & Zurek AM. Patient perceptions of generic drugs: dispelling misconceptions. US Pharm. 2016;41 (Generic Drug Review suppl):36–41.



James Visanji Tribute
President’s Message
Regulatory pathways for development and submission activities
Biosimilar development – an overview
Statistical principles in biosimilar development
Writing biosimilar clinical study reports and submission documents – what to expect and what to consider
Medical writing for generics throughout the life cycle
Same but different: Basic tools for biosimilar and generic pharmacovigilance writing
Layperson materials in the sphere of biosimilars and generic medicines
Insulin biosimilars
Biosimilars: Change, challenge, and accomplishments
ICMJE requirements for sharing individual participant data from interventional clinical trials
Medicinal products and medical devices in clinical trials conduct and disclosure
Publication of clinical trial protocols and statistical analysis plans on
Collecting metrics in medical writing – the benefits to you and your business
Document management systems for medical writing
Winner of the Geoff Hall Scholarship Essay Competition
Regulatory Matters
News from the EMA
Getting Your Foot in the Door
Veterinary Medical Writing
Teaching Medical Writing
Medical Devices
My First Medical Writing
Journal Watch
Good Writing Practice
Regulatory Public Disclosure
Out on Our Own


The Write Stuff Archive Contact Instructions for Authors Article Template (Word) Journal Policies

Editoral Board


Raquel Billiones


Evguenia Alechine

Jonathan Pitt

Managing Editor

Victoria White

Associate Editors

Anuradha Alahari

Jennifer Bell

Nicole Bezuidenhout

Claire Chang

Barbara Grossman

Sarah Milner

John Plant

Sampoorna Rappaz

Amy Whereat

Section Editors

Daniela Kamir


Jennifer Bell


Nicole Bezuidenhout 

Digital Communication

Somsuvro Basu

EMWA News 

Ana Sofia Correia 

Gained in Translation

Ivana Turek

Getting Your Foot in the Door

Wendy Kingdom / Amy Whereat

Good Writing Practice

Alison McIntosh 

In the Bookstores

Maria Kołtowska-Häggström

Lingua Franca and Beyond

Maddy Dyer


Lisa Chamberlain-James

Medical Communications/Writing for Patients

Payal Bhatia

Medical Devices

Evguenia Alechine

My First Medical Writing

Anuradha Alahari

News from the EMA

Adriana Rocha


Tiziana von Bruchhausen


Clare ChangZuo Yen Lee 

Regulatory Matters

Sam Hamilton

Regulatory Public Disclosure

Claire Gudex

Teaching Medical Writing

Louisa Ludwig-Begall / Sarah Kabani

The Crofter: Sustainable Communications

Louisa Marcombes

Veterinary Writing

Editors Emeritus

Elise Langdon-Neuner

Phil Leventhal

Layout Designer

Chris Monk